PSP vs CBS Phenotypic Divergence: Mechanistic Comparison

PSP vs CBS Phenotypic Divergence: Mechanistic Comparison

Overview

Progressive Supranuclear Palsy ([PSP](/diseases/progressive-supranuclear-palsy)) and Corticobasal Syndrome ([CBS](/diseases/corticobasal-syndrome)) are both classified as 4R-tauopathies, diseases characterized by the predominant accumulation of tau isoforms containing four microtubule-binding repeats. Despite this shared molecular pathology — and considerable overlap in their genetic architecture — the two conditions produce strikingly different clinical syndromes. Understanding the mechanistic basis for this phenotypic divergence is central to developing targeted therapies for each condition.

PSP-RS presents with early postural instability, vertical supranuclear gaze palsy, and axial akinesia, reflecting vulnerability of brainstem and basal ganglia structures. CBS, by contrast, is defined by asymmetric cortical signs — apraxia, alien limb phenomenon, cortical sensory loss — reflecting damage to motor and parietal cortical regions. The divergence emerges from differences in: (1) genetic risk profiles, (2) regional patterns of neuronal vulnerability, (3) tau filament conformations, (4) neuroimmune contributions, and (5) spreading mechanisms.

1. Clinical Divergence

1.1 PSP Richardson Syndrome (PSP-RS)

PSP-RS is the most common PSP phenotype, accounting for 50-55% of pathologically confirmed cases[@williams2005]. The cardinal features are:

PSP vs CBS Phenotypic Divergence: Mechanistic Comparison

Overview

Progressive Supranuclear Palsy ([PSP](/diseases/progressive-supranuclear-palsy)) and Corticobasal Syndrome ([CBS](/diseases/corticobasal-syndrome)) are both classified as 4R-tauopathies, diseases characterized by the predominant accumulation of tau isoforms containing four microtubule-binding repeats. Despite this shared molecular pathology — and considerable overlap in their genetic architecture — the two conditions produce strikingly different clinical syndromes. Understanding the mechanistic basis for this phenotypic divergence is central to developing targeted therapies for each condition.

PSP-RS presents with early postural instability, vertical supranuclear gaze palsy, and axial akinesia, reflecting vulnerability of brainstem and basal ganglia structures. CBS, by contrast, is defined by asymmetric cortical signs — apraxia, alien limb phenomenon, cortical sensory loss — reflecting damage to motor and parietal cortical regions. The divergence emerges from differences in: (1) genetic risk profiles, (2) regional patterns of neuronal vulnerability, (3) tau filament conformations, (4) neuroimmune contributions, and (5) spreading mechanisms.

1. Clinical Divergence

1.1 PSP Richardson Syndrome (PSP-RS)

PSP-RS is the most common PSP phenotype, accounting for 50-55% of pathologically confirmed cases[@williams2005]. The cardinal features are:

• Vertical supranuclear gaze palsy (VSGP): Impaired downward gaze is the most characteristic early sign. Patients lose the ability to look down voluntarily before upward gaze is affected. Horizontal saccades are also progressively impaired[@hoglinger2017].
• Postural instability with early falls: Backward falls within the first year are a defining feature, reflecting damage to the midbrain pedunculopontine nucleus and vestibular integration centers.
• Axial akinesia and rigidity: "Axial predominant" motor pattern with early neck extension (retrocollis) and generalized akinesia out of proportion to limb rigidity.
• Pseudobulbar features: Dysarthria, dysphagia, and emotional incontinence occur early.
• Frontal cognitive dysfunction: Executive impairment, slowed processing speed, and behavioral changes mirror frontostriatal circuit disruption.

1.2 Corticobasal Syndrome (CBS)

CBS is defined by asymmetric cortical signs combined with extrapyramidal features[@armstrong2013]:

• Asymmetric limb apraxia: Inability to perform learned motor tasks on command, affecting the dominant hand first. Distal > proximal, left more common than right.
• Alien limb phenomenon: Patient's limb appears to act autonomously, with grasping, levitation, and resistive behaviors the patient cannot suppress.
• Cortical sensory loss: Impaired two-point discrimination, stereognosis, and graphesthesia despite intact primary sensation.
• Myoclonus: Action myoclonus, often stimulus-sensitive, in the affected limb.
• Asymmetric dystonia: Typically affects the hand and arm in an akinetic-rigid pattern.
• Cognitive features: Visuospatial dysfunction, non-fluent aphasia, and executive impairment reflecting asymmetric frontoparietal involvement.

1.3 Pathological Correlates of Clinical Divergence

The clinical features map to distinct neuroanatomical substrates[@boeve2003][@kouri2011]:

| Clinical Feature | PSP-RS Anatomical Basis | CBS Anatomical Basis |
|---|---|---|
| Vertical gaze palsy | Midbrain superior colliculus, rostral interstitial nucleus of MLF | Parietal eye fields, frontal eye fields |
| Early falls | Subthalamic nucleus, pedunculopontine nucleus | Posterior parietal cortex, supplementary motor area |
| Asymmetric apraxia | Bilateral basal ganglia (less affected) | Asymmetric motor cortex, premotor cortex, corpus callosum |
| Alien limb | Minimal involvement | Primary somatosensory cortex, superior parietal lobule |
| Axial vs limb rigidity | Midbrain reticular formation | Asymmetric basal ganglia output |

2. Genetic Risk Factors

2.1 MAPT H1/H2 Haplotypes

The MAPT gene on chromosome 17q21 encodes tau protein. Two major haplotypes — H1 and H2 — exist due to a 900 kb inversion polymorphism. The H1 haplotype is the major risk factor for both PSP and CBS, but with important quantitative differences[@wen2023][@chen2021]:

• PSP: Strong association with H1/H1 genotype. OR approximately 5-8 for H1/H1 vs H2/H2. Multiple H1-specific variants contribute, including rs242557 (MAPT cis-regulatory element).
• CBS/CBD: H1/H1 association is present but weaker (OR ~2-4). H2 haplotype may be slightly protective, similar to PSP.

• PSP-specific: rs242557 (A allele), rs4792891, rs7216058
• Shared or less specific: rs1052553 (exon 3 skip variant, minor allele A associated with reduced 3R tau)

2.2 TMEM106B

TMEM106B polymorphisms influence lysosomal function and have been associated with TDP-43 proteinopathies. Recent evidence suggests:

• TMEM106B rs3173615 (T185S) affects progranulin levels and may modulate neuroinflammation
• The protective allele (T185) is less common in both PSP and CBS
• TMEM106B effects appear more pronounced in PSP than CBS, potentially via microglial modulation of tau spreading[@sepulvedafalla2022]

2.3 LRRK2 and CBS-Specific Genetics

LRRK2 G2019S mutations — more commonly associated with Parkinson's disease — are found in a subset of CBS cases, particularly those with asymmetric presentations:

• LRRK2-associated CBS cases often show PSD-95 positive inclusions alongside tau pathology
• This suggests LRRK2 mutations may drive CBS through distinct pathways involving kinase dysregulation
• The mechanistic link between LRRK2 and 4R-tau pathology remains under investigation

2.4 Shared vs. Divergent Genetic Architecture

Genome-wide association studies reveal substantial genetic overlap between PSP and CBD[@chen2021]:

• Shared risk loci include MAPT H1 region and chromosome 2p13 (EPS8L3)
• PSP-specific signal near STX6 (involved in vesicular trafficking)
• CBD-specific signal near ARAP1

3. Regional Vulnerability Differences

3.1 PSP: Midbrain and Basal Ganglia Predominance

PSP pathology preferentially targets structures with dense tau expression under normal conditions:

• Subthalamic nucleus (STN): Among the highest tau-expressing regions in the human brain. Early pretangle and coiled body formation drives the characteristic early falls and axial symptoms.
• Globus pallidus interna (GPi): Tau accumulation in the output nucleus of the basal ganglia drives the axial akinesia and rigidity characteristic of PSP-RS.
• Substantia nigra pars compacta: Neuronal loss contributes to the parkinsonian features, but unlike PD, dopamine replacement therapy is ineffective.
• Midbrain tectum: Involvement of the superior colliculus explains the vertical gaze palsy.
• Dentate nucleus of cerebellum: Contributes to the PSP phenotype through disruption of cerebellar-thalamic loops.

3.2 CBS: Asymmetric Cortical and Basal Ganglia Involvement

CBS targets lateralized cortical circuits:

• Motor cortex (Brodmann areas 4, 6): Asymmetric involvement produces the characteristic apraxia and alien limb. Layer V pyramidal neurons are particularly vulnerable.
• Parietal cortex (BA 5, 7): Loss of somatosensory association cortex drives cortical sensory loss and visuospatial dysfunction.
• Basal ganglia (putamen > globus pallidus): Asymmetric striatal involvement contributes to the limb dystonia and rigidity.
• Corpus callosum: Transcallosal degeneration allows interhemispheric spread and may contribute to the alien limb phenomenon.
• Thalamus: Ventral posterior and ventral lateral nuclei show involvement correlating with sensory and motor deficits.

3.3 Cell-Type Specific Vulnerability

Both conditions show particular vulnerability of specific neuronal populations:

| Cell Type | PSP Vulnerability | CBS Vulnerability |
|---|---|---|
| Pyramidal neurons (cortical layer V) | Moderate | High (asymmetric) |
| Striatal medium spiny neurons | High | Moderate |
| Subthalamic nucleus neurons | Very high | Low |
| Midbrain oculomotor neurons | High | Low |
| Pontine nuclei | High | Low |
| Cerebellar Purkinje cells | Moderate | Low |

The molecular basis of this differential vulnerability involves region-specific tau expression levels, neuronal morphology, electrophysiological properties, and local immune microenvironment.

4. Tau Isoform and Conformational Differences

4.1 4R Tau Predominance

Both PSP and CBS are 4R-tauopathies, meaning that the accumulated tau filaments contain predominantly the 4-repeat isoforms (3R:4R ratio approaches 0:1 in most cases, compared to 1:1 in Alzheimer's disease where both 3R and 4R tangles are present). The exclusive use of 4R tau distinguishes both from Pick disease (3R tauopathy) and AD (mixed 3R+4R)[@goedert2018].

The critical distinction between PSP and CBS is not the 4R:3R ratio itself, but rather:

4.2 Filament Conformations (Tau Strains)

Cryo-EM studies have revealed that different tauopathies produce distinct filament structures[@goedert2018]:

• PSP filaments: The PSP-type fold shows a compact C-shaped conformation with specific residues (Lys-234, Val-306) involved in the core. The filaments show a "pillown" appearance on EM.
• CBD filaments: Corticobasal degeneration produces a distinct filament fold with different protease-resistant core boundaries. The CBD fold includes residues from the repeat domain that are excluded from PSP filaments.
• These structural differences constitute "strains" — distinct conformers that propagate templating of identical conformation, analogous to prion strains.

4.3 Conformational Determinants

Key structural differences between PSP and CBD tau filaments:

5. Neuroimmune Contributions

5.1 Microglial Activation Profiles

Neuroinflammation plays a differential role in PSP vs CBS[@sepulvedafalla2022]:

PSP:

• Prominent activation of Iba1+ microglia in the basal ganglia and midbrain
• TREM2 expression is increased in PSP brains — the TREM2 Q317 variant shows nominal association with PSP risk
• Microglial morphology in PSP suggests a surveillance (M0) to neurotoxic (M1) shift in affected regions
• TSPO PET imaging shows increased binding in brainstem and basal ganglia in PSP

• Asymmetric microglial activation mirrors the cortical pattern of atrophy
• CD33 (sialic acid-binding Ig-like lectin 3) polymorphisms affect microglial phagocytosis and have been associated with CBS/CBD risk
• TREM2 variants show weaker association with CBS than PSP
• Neuroinflammation may be more pronounced in CBS cases with concomitant AD pathology

5.2 Astrocyte Involvement

Astrocyte reactivity differs between the conditions:

• PSP: Predominantly subcortical astrocyte involvement with GFAP+ astrocytes in basal ganglia. Cortical astrocyte pathology is less prominent.
• CBS: Asymmetric cortical astrocyte involvement, with many cases showing "astrocytic plaques" (the CBD-specific astrocytic tau pathology). This distinctive pattern — tau accumulation in astrocytic processes — is highly specific for CBD neuropathology.

5.3 Inflammatory Cytokines and Biomarkers

CSF and plasma studies reveal:

• NFL (neurofilament light chain): Elevated in both conditions, higher in PSP-RS than CBS
• Tau (total and phosphorylated): Both conditions show elevated p-tau181, but CBS cases with underlying AD show higher p-tau217
• GFAP: May be more elevated in CBS with significant cortical involvement
• IL-6, TNF-alpha: Variable elevations in both conditions; TSPO PET shows more inflammation in PSP brainstem

6. Clinical Trial Overlap and Divergence

6.1 Shared Therapeutic Targets

Both conditions target common pathways:

• Tau aggregation inhibition: Lithium, methylene blue derivatives, and small molecule aggrega-tion inhibitors have been tested in both conditions
• Tau antisense oligonucleotides (ASOs): BIIB080 (MAPT-targeting ASO) is in trials for PSP and CBD as part of the TauNex program
• Immunotherapy: Aducanumab, semorinemab, and other anti-tau antibodies have been tested in PSP (NCT02880956) and CBD (various)

6.2 Disease-Specific Trials

| Agent | Target | PSP Trial | CBS Trial |
|---|---|---|---|
| Tideglusib (GSK-3 inhibitor) | GSK3B | Phase II (negative) | Phase II (negative) |
| Davunetide (granin peptide) | Neuroprotection | Phase II/III (negative) | No |
| BIIB080 (MAPT ASO) | Tau mRNA | Phase I/II recruiting | Phase I/II recruiting |
| Bepranserastat (TDF-853) | CK1delta | Phase I (PSP) | No |
| Semorinemab (anti-tau mAb) | Tau extracellular | Phase II (negative) | Phase II (ongoing) |

6.3 Key Divergence in Trial Design

• Outcome measures differ: PSP trials use PSP-Scale (PSPS), vertical saccade velocity; CBS trials use CBS-CGI-C, Jebsen Taylor test
• Population heterogeneity: CBS trials must account for the fact that ~50% of CBS patients have underlying AD pathology (ADNC), which confounds tau-targeting approaches
• Biomarker stratification: CSF p-tau217 and tau PET can distinguish AD-cBBS from primary 4R-tau CBS, allowing enriched trial designs

7. Mechanistic Model

The following diagram summarizes the convergent and divergent pathways underlying the phenotypic split between PSP and CBS:

The model illustrates how a common H1-driven 4R-tauopathy foundation diverges into two clinically distinct syndromes through: (1) initial seeding site (brainstem vs. cortex), (2) region-specific neuronal vulnerability patterns, (3) distinct tau filament strains that preferentially propagate in specific neuronal populations, and (4) differential neuroimmune contributions.

8. Cross-Links to Related Pages

• [4R-Tauopathies Overview](/mechanisms/4r-tauopathy-mechanisms)
• [4R-Tau Genetic Comparison](/mechanisms/4r-tauopathy-genetic-comparison)
• [Brain Region Vulnerability in 4R-Tauopathies](/mechanisms/4r-tauopathies-brain-region-vulnerability)
• [Neuroimmune Response in 4R-Tauopathies](/mechanisms/4r-tauopathies-neuroimmune-comparison)
• [4R-Tau Cell Vulnerability](/diseases/4r-tauopathy-cell-vulnerability)
• [Tau Spreading in 4R-Tauopathies](/mechanisms/4r-tauopathy-spreading-comparison)
• [PSP-CBD Overlap Syndrome](/diseases/psp-cbd-overlap)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [PSP Richardson Syndrome](/diseases/progressive-supranuclear-palsy-richardson-syndrome)
• [Tau Protein](/proteins/tau)
• [MAPT Gene](/genes/mapt)

References